Exact Sciences posted strong Q4 revenue growth but faced a significant EPS miss. Find out why I remain bullish on EXAS stock.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q4 CY2024, with sales ...

BTIG analyst Mark Massaro maintained a Buy rating on Exact Sciences (EXAS – Research Report) yesterday and set a price target of $65.00. The ...

Scotiabank raised the firm’s price target on Exact Sciences (EXAS) to $73 from $70 and keeps an Outperform rating on the shares. Exact’s Q4 was ...

Rhumbline Advisers lowered its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 2.7% during the fourth ...

CIBC Asset Management Inc raised its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 14.0% in the fourth ...

Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company ...

Operator Good day, everyone, and welcome to the Exact Sciences fourth quarter 2024 earnings call. Today's call is being ...

Exact Sciences reports strong Q4 2024 growth, unveils 2025 plans with 11% revenue growth forecast & Cologuard Plus launch.

Learn more about whether Exact Sciences Corporation or Twist Bioscience Corporation is a better investment based on AAII's A+ ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Wednesday reported a loss of $864.6 million in its fourth quarter. On a per-share basis, the Madison, Wisconsin-based company ...